Hip OsteoarthritisNCT07288983
PENG Block vs Suprainguinal FICB vs Lumbar ESPB for Analgesia After Hip Surgery
A study testing Pericapsular Nerve Group (PENG) Block, Suprainguinal Fascia Iliaca Compartment Block (S-FICB) and Lumbar Erector Spinae Plane Block (L-ESPB) in people with Hip Osteoarthritis, run by Poznan University of Medical Sciences at 1 site in Poland.
Trial summary
This randomized, double-blinded, controlled clinical trial compares three motor-sparing regional anesthesia techniques used for postoperative analgesia in patients undergoing hip arthroplasty: the Pericapsular Nerve Group (PENG) block, the suprainguinal Fascia Iliaca Compartment Block (S-FICB), and the Lumbar Erector… Read more about this study
- Who is it for?
- Ages 65 to 100 years
- Conditions the study is for
- Hip Osteoarthritis
- What is being tested?
- Pericapsular Nerve Group (PENG) Block, Suprainguinal Fascia Iliaca Compartment Block (S-FICB) and Lumbar Erector Spinae Plane Block (L-ESPB)
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 93 participants
- Where
- 1 sitePoland
- Study dates
- 6 Feb 2026to 31 Jan 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 to 100 years
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- Adults aged 65 years or older scheduled to undergo elective hip arthroplasty under spinal anesthesia.
- Ability to provide written informed consent.
- Ability to understand and reliably use numerical pain assessment tools (NRS 0-10).
- ASA physical status II-III.
- Expected postoperative hospitalization of at least 48 hours to ensure complete data collection.
Who cannot join
- Inability to provide informed consent due to cognitive impairment, language barrier, or severe hearing/speech limitations.
- Coagulopathy or therapeutic anticoagulation not meeting safety criteria for regional anesthesia.
- Local infection at the planned block site.
- Allergy, hypersensitivity, or contraindication to ropivacaine, local anesthetics, or study medications.
- Pre-existing lower-limb neurological deficits (motor or sensory) affecting outcome assessments.
- Severe spinal deformity or anatomical limitations preventing safe performance of regional blocks.
Show all 12Show fewer
- Chronic opioid use (defined as >30 mg oral morphine equivalents daily for more than 2 weeks).
- Severe renal failure (eGFR <30 mL/min/1.73m²) or severe hepatic impairment.
- Uncontrolled diabetes mellitus (fasting glucose >300 mg/dL or HbA1c >10%).
- History of local anesthetic systemic toxicity (LAST).
- Participation in another interventional clinical trial within the past 30 days.
- Any condition deemed by investigators to interfere with protocol adherence, safety monitoring, or outcome reliability.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Poland1 site, 1 recruiting
- Recruiting
Poznan University of Medical Sciences
Poznan, 62-701
Malgorzata Reysner, M.D. Ph.D., +48 61 873 83 03, mreysner@ump.edu.pl
About this study
Official title: A Randomized, Double-Blinded, Controlled Trial Comparing the Analgesic Efficacy and Motor-Sparing Properties of the Pericapsular Nerve Group (PENG) Block, Suprainguinal Fascia Iliaca Compartment Block (S-FICB), and Lumbar Erector Spinae Plane Block (L-ESPB) in Patients Undergoing Hip Arthroplasty
This randomized, double-blinded, controlled clinical trial compares three motor-sparing regional anesthesia techniques used for postoperative analgesia in patients undergoing hip arthroplasty: the Pericapsular Nerve Group (PENG) block, the suprainguinal Fascia Iliaca Compartment Block (S-FICB), and the Lumbar Erector Spinae Plane Block (L-ESPB). Although all three techniques are widely used in modern hip surgery, their relative analgesic efficacy, opioid-sparing potential, and impact on early functional recovery have not been directly compared in a single study.
The primary objective is to determine which block provides the most effective postoperative analgesia while preserving motor function and facilitating early mobilization. Secondary objectives include comparisons of opioid consumption, pain scores at rest and during movement, time to first rescue analgesia, block-related adverse events, quadriceps strength, incidence of postoperative nausea and vomiting, and early functional outcomes.
This study aims to identify the optimal motor-sparing regional anesthesia strategy for older adults undergoing hip arthroplasty.
Read the detailed description
Regional anesthesia plays a key role in modern multimodal analgesia for hip arthroplasty, particularly in older adults who are vulnerable to opioid-related adverse effects and postoperative functional decline. Several motor-sparing nerve block techniques have been developed to improve postoperative pain control while maintaining quadriceps strength and enabling early mobilization. Among them, the Pericapsular Nerve Group (PENG) block, the suprainguinal Fascia Iliaca Compartment Block (S-FICB), and the Lumbar Erector Spinae Plane Block (L-ESPB) are widely used in clinical practice. However, no randomized clinical trial has directly compared these three approaches within a single study population.
The PENG block targets the articular branches of the femoral, obturator, and accessory obturator nerves, providing selective analgesia of the anterior hip capsule with minimal motor involvement. The suprainguinal FICB delivers a higher spread of local anesthetic over the femoral nerve, lateral femoral cutaneous nerve, and variable portions of the obturator nerve, offering broader sensory coverage but with a higher likelihood of quadriceps weakness. The lumbar ESPB is a posterior fascial plane block that may achieve indirect spread toward the lumbar plexus, potentially providing balanced anterior and posterior capsular analgesia while preserving motor function.
This randomized, double-blinded, three-arm controlled trial aims to compare the analgesic effectiveness, opioid-sparing properties, and motor-sparing characteristics of PENG, S-FICB, and L-ESPB in patients undergoing hip arthroplasty. All participants will receive standardized spinal anesthesia and multimodal postoperative analgesia. The study's primary endpoint is the time to first rescue opioid administration. Secondary outcomes include total postoperative opioid consumption, pain scores at rest and during movement, quadriceps muscle strength, block performance time, incidence of postoperative nausea and vomiting, early mobilization parameters, and block-related adverse events.
The results of this trial are expected to clarify the relative benefits and limitations of the three most commonly used motor-sparing regional anesthesia techniques for hip surgery and to guide optimal selection of blocks for enhanced recovery pathways in older adults undergoing hip arthroplasty.
- Conditions
- Hip Osteoarthritis
- Being tested
- Pericapsular Nerve Group (PENG) Block, Suprainguinal Fascia Iliaca Compartment Block (S-FICB), Lumbar Erector Spinae Plane Block (L-ESPB)
- Medical subject headings
- Osteoarthritis, Hip
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pericapsular Nerve Group (PENG) BlockProcedure or surgery
The Pericapsular Nerve Group (PENG) block will be performed under ultrasound guidance using a curvilinear or linear transducer. A 22-gauge echogenic needle will be advanced in-plane toward the fascial plane between the iliopsoas tendon and the pelvic brim at the level of the anterior inferior iliac spine. A total of 20 mL of 0.2% ropivacaine will be injected incrementally with repeated aspiration to avoid intravascular injection. No additional peripheral nerve blocks will be performed. All patients will receive standardized spinal anesthesia and multimodal postoperative analgesia.
Suprainguinal Fascia Iliaca Compartment Block (S-FICB)Procedure or surgery
The suprainguinal fascia iliaca compartment block will be performed under ultrasound guidance using a high-frequency linear probe placed in the sagittal oblique plane above the inguinal ligament. After identifying the fascia iliaca above the iliacus muscle, a 22-gauge echogenic needle will be advanced in-plane into the suprainguinal fascia iliaca space. A total of 30 mL of 0.2% ropivacaine will be injected to achieve cranial spread toward the femoral nerve, lateral femoral cutaneous nerve, and obturator nerve. All patients will receive standardized spinal anesthesia and multimodal postoperative analgesia.
Lumbar Erector Spinae Plane Block (L-ESPB)Procedure or surgery
The lumbar erector spinae plane block will be performed under ultrasound guidance at the L4 transverse process level. A curvilinear or linear ultrasound probe will be used to identify the erector spinae muscle and underlying transverse process. A 22-gauge echogenic needle will be inserted in-plane and advanced to the fascial plane deep to the erector spinae muscle and superficial to the transverse process. A total of 20 mL of 0.2% ropivacaine will be injected incrementally. No sacral ESPB will be added. All patients will receive standardized spinal anesthesia and multimodal postoperative analgesia.
| Study group | Role | What they receive |
|---|---|---|
| PENG block | Active comparator | Participants in this arm will receive a Pericapsular Nerve Group (PENG) block performed under ultrasound guidance. The block will be administered with 20 mL of 0.2% ropivacaine injected lateral to the iliopsoas tendon at the level of the anterior inferior iliac spine and iliopubic eminence. No additional peripheral nerve blocks will be performed. All participants will receive standardized spinal anesthesia and multimodal postoperative analgesia. Receives: Procedure: Pericapsular Nerve Group (PENG) Block |
| Suprainguinal FICB | Active comparator | Participants will receive a suprainguinal Fascia Iliaca Compartment Block (S-FICB) performed under ultrasound guidance. A total of 40 mL of 0.2% ropivacaine will be injected in the suprainguinal fascia iliaca plane to achieve spread toward the femoral nerve, lateral femoral cutaneous nerve, and obturator nerve. All participants will receive standardized spinal anesthesia and multimodal postoperative analgesia. Receives: Procedure: Suprainguinal Fascia Iliaca Compartment Block (S-FICB) |
| Lumbar ESPB | Active comparator | Participants will receive a lumbar Erector Spinae Plane Block (L-ESPB) performed under ultrasound guidance at the L4 transverse process level. A total of 20 mL of 0.2% ropivacaine will be injected deep to the erector spinae muscle and superficial to the transverse process. No sacral ESPB will be added. All participants will receive standardized spinal anesthesia and multimodal postoperative analgesia. Receives: Procedure: Lumbar Erector Spinae Plane Block (L-ESPB) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Total Opioid Consumption in the First 48 Hours After Surgery
Total cumulative opioid consumption recorded in the first 48 postoperative hours, converted to morphine milligram equivalents (MME). Includes all opioid medications administered as part of postoperative analgesia, both scheduled and rescue doses. Data will be extracted from electronic medication records and converted using standard MME conversion factors.
Measured: 0-48 hours postoperatively
Secondary outcomes (19)
Time to First Rescue Opioid Administration
Time in hours from the end of surgery to the first administration of rescue opioid analgesia (5 mg intravenous oxycodone) triggered by a Numerical Rating Scale (NRS) pain score ≥ 4 or patient request.
Measured: 0-48 hours postoperatively
Numerical Rating Scale (NRS) Pain Scores at Rest
Pain intensity at rest measured using the 0-10 Numerical Rating Scale (0 = no pain, 10 = worst pain). Pain will be assessed by blinded study personnel at predefined intervals.
Measured: 4 hours postoperatively
Numerical Rating Scale (NRS) Pain Scores at Rest
Pain intensity at rest measured using the 0-10 Numerical Rating Scale (0 = no pain, 10 = worst pain). Pain will be assessed by blinded study personnel at predefined intervals.
Measured: 8 hours postoperatively
Numerical Rating Scale (NRS) Pain Scores at Rest
Pain intensity at rest measured using the 0-10 Numerical Rating Scale (0 = no pain, 10 = worst pain). Pain will be assessed by blinded study personnel at predefined intervals.
Measured: 12 hours postoperatively
Numerical Rating Scale (NRS) Pain Scores at Rest
Pain intensity at rest measured using the 0-10 Numerical Rating Scale (0 = no pain, 10 = worst pain). Pain will be assessed by blinded study personnel at predefined intervals.
Measured: 24 hours postoperatively
Numerical Rating Scale (NRS) Pain Scores at Rest
Pain intensity at rest measured using the 0-10 Numerical Rating Scale (0 = no pain, 10 = worst pain). Pain will be assessed by blinded study personnel at predefined intervals.
Measured: 48 hours postoperatively
Numerical Rating Scale (NRS) Pain Scores During Movement
Pain intensity during passive hip flexion or standardized physiotherapy-assisted mobilization using the 0-10 Numerical Rating Scale (0 = no pain, 10 = worst pain). Assessments performed by blinded study staff.
Measured: 4 hours postoperatively
Numerical Rating Scale (NRS) Pain Scores During Movement
Pain intensity during passive hip flexion or standardized physiotherapy-assisted mobilization using the 0-10 Numerical Rating Scale (0 = no pain, 10 = worst pain). Assessments performed by blinded study staff.
Measured: 8 hours postoperatively
Numerical Rating Scale (NRS) Pain Scores During Movement
Pain intensity during passive hip flexion or standardized physiotherapy-assisted mobilization using the 0-10 Numerical Rating Scale (0 = no pain, 10 = worst pain). Assessments performed by blinded study staff.
Measured: 12 hours postoperatively
Numerical Rating Scale (NRS) Pain Scores During Movement
Pain intensity during passive hip flexion or standardized physiotherapy-assisted mobilization using the 0-10 Numerical Rating Scale (0 = no pain, 10 = worst pain). Assessments performed by blinded study staff.
Measured: 24 hours postoperatively
Numerical Rating Scale (NRS) Pain Scores During Movement
Pain intensity during passive hip flexion or standardized physiotherapy-assisted mobilization using the 0-10 Numerical Rating Scale (0 = no pain, 10 = worst pain). Assessments performed by blinded study staff.
Measured: 48 hours postoperatively
Quadriceps Muscle Strength
Motor strength of knee extension and hip adduction assessed using the Medical Research Council (MRC) scale (0 = no contraction; 5 = normal strength) by two blinded assessors.
Measured: 4 hours postoperatively
Quadriceps Muscle Strength
Motor strength of knee extension and hip adduction assessed using the Medical Research Council (MRC) scale (0 = no contraction; 5 = normal strength) by two blinded assessors.
Measured: 8 hours postoperatively
Quadriceps Muscle Strength
Motor strength of knee extension and hip adduction assessed using the Medical Research Council (MRC) scale (0 = no contraction; 5 = normal strength) by two blinded assessors.
Measured: 12 hours postoperatively
Quadriceps Muscle Strength
Motor strength of knee extension and hip adduction assessed using the Medical Research Council (MRC) scale (0 = no contraction; 5 = normal strength) by two blinded assessors.
Measured: 24 hours postoperatively
Quadriceps Muscle Strength
Motor strength of knee extension and hip adduction assessed using the Medical Research Council (MRC) scale (0 = no contraction; 5 = normal strength) by two blinded assessors.
Measured: 48 hours postoperatively
Incidence of Postoperative Nausea and Vomiting (PONV)
Presence of nausea, vomiting, or use of antiemetic medications documented by nursing staff and confirmed by blinded investigators.
Measured: 0-24 hours postoperatively
Time to First Mobilization
Time in hours from the end of surgery until the patient is able to stand with physiotherapist assistance. Early mobilization follows institutional enhanced recovery protocols.
Measured: 0-48 hours postoperatively
Adverse Events Related to Regional Anesthesia
Incidence of block-related complications including vascular puncture, local anesthetic systemic toxicity, persistent sensory deficit, motor deficit, or nerve injury as documented in hospital records.
Measured: Up to 48 hours postoperatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Dec 2025
- Study start6 Feb 2026
- Primary completion1 Jan 2027 (estimated)
- Study completion31 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hip OsteoarthritisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 93 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Poznan University of Medical Sciences
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Malgorzata Reysner, MD PhD, Study chair, Poznań University of Medicla Sciences
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07288983
- Sponsor's protocol ID
- 14/2025
- Status last verified
- Dec 2025
- First submitted
- 4 Dec 2025
- Last updated
- 4 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified individual participant data (IPD) underlying the primary and secondary outcome analyses will be made available to other researchers upon reasonable request. Shared data will include demographic variables, intraoperative information, block-related details, pain scores, opioid consumption, motor assessments, and adverse events. No direct identifiers or protected health information will be included.
Study at a glance
From the registry record, last updated by the sponsor on 4 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-Blinded, Controlled Trial Comparing the Analgesic Efficacy and Motor-Sparing Properties of the Pericapsular Nerve Group (PENG) Block, Suprainguinal Fascia Iliaca Compartment Block (S-FICB), and Lumbar Erector Spinae Plane Block (L-ESPB) in Patients Undergoing Hip Arthroplasty
- ClinicalTrials.gov ID
- NCT07288983
- Acronym / sponsor ID
- 14/2025
- Conditions
- Hip Osteoarthritis
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 93 participants (estimated)
- Lead sponsor
- Poznan University of Medical SciencesUniversity, hospital or other
- Study start
- 6 Feb 2026 (actual)
- Primary completion
- 1 Jan 2027 (estimated)
- Study completion
- 31 Jan 2027 (estimated)
- First posted
- 17 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized, double-blinded, controlled clinical trial compares three motor-sparing regional anesthesia techniques used for postoperative analgesia in patients undergoing hip arthroplasty: the Pericapsular Nerve Group (PENG) block, the suprainguinal Fascia Iliaca Compartment Block (S-FICB), and the Lumbar Erector Spinae Plane Block (L-ESPB). Although all three techniques are widely used in modern hip surgery, their relative analgesic efficacy, opioid-sparing potential, and impact on early functional recovery have not been directly compared in a single study.
The primary objective is to determine which block provides the most effective postoperative analgesia while preserving motor function and facilitating early mobilization. Secondary objectives include comparisons of opioid consumption, pain scores at rest and during movement, time to first rescue analgesia, block-related adverse events, quadriceps strength, incidence of postoperative nausea and vomiting, and early functional outcomes.
This study aims to identify the optimal motor-sparing regional anesthesia strategy for older adults undergoing hip arthroplasty.
Detailed description
Regional anesthesia plays a key role in modern multimodal analgesia for hip arthroplasty, particularly in older adults who are vulnerable to opioid-related adverse effects and postoperative functional decline. Several motor-sparing nerve block techniques have been developed to improve postoperative pain control while maintaining quadriceps strength and enabling early mobilization. Among them, the Pericapsular Nerve Group (PENG) block, the suprainguinal Fascia Iliaca Compartment Block (S-FICB), and the Lumbar Erector Spinae Plane Block (L-ESPB) are widely used in clinical practice. However, no randomized clinical trial has directly compared these three approaches within a single study population.
The PENG block targets the articular branches of the femoral, obturator, and accessory obturator nerves, providing selective analgesia of the anterior hip capsule with minimal motor involvement. The suprainguinal FICB delivers a higher spread of local anesthetic over the femoral nerve, lateral femoral cutaneous nerve, and variable portions of the obturator nerve, offering broader sensory coverage but with a higher likelihood of quadriceps weakness. The lumbar ESPB is a posterior fascial plane block that may achieve indirect spread toward the lumbar plexus, potentially providing balanced anterior and posterior capsular analgesia while preserving motor function.
This randomized, double-blinded, three-arm controlled trial aims to compare the analgesic effectiveness, opioid-sparing properties, and motor-sparing characteristics of PENG, S-FICB, and L-ESPB in patients undergoing hip arthroplasty. All participants will receive standardized spinal anesthesia and multimodal postoperative analgesia. The study's primary endpoint is the time to first rescue opioid administration. Secondary outcomes include total postoperative opioid consumption, pain scores at rest and during movement, quadriceps muscle strength, block performance time, incidence of postoperative nausea and vomiting, early mobilization parameters, and block-related adverse events.
The results of this trial are expected to clarify the relative benefits and limitations of the three most commonly used motor-sparing regional anesthesia techniques for hip surgery and to guide optimal selection of blocks for enhanced recovery pathways in older adults undergoing hip arthroplasty.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| PENG block | Active comparator | Procedure: Pericapsular Nerve Group (PENG) BlockParticipants in this arm will receive a Pericapsular Nerve Group (PENG) block performed under ultrasound guidance. The block will be administered with 20 mL of 0.2% ropivacaine injected lateral to the iliopsoas tendon at the level of the anterior inferior iliac spine and iliopubic eminence. No additional peripheral nerve blocks will be performed. All participants will receive standardized spinal anesthesia and multimodal postoperative analgesia. |
| Suprainguinal FICB | Active comparator | Procedure: Suprainguinal Fascia Iliaca Compartment Block (S-FICB)Participants will receive a suprainguinal Fascia Iliaca Compartment Block (S-FICB) performed under ultrasound guidance. A total of 40 mL of 0.2% ropivacaine will be injected in the suprainguinal fascia iliaca plane to achieve spread toward the femoral nerve, lateral femoral cutaneous nerve, and obturator nerve. All participants will receive standardized spinal anesthesia and multimodal postoperative analgesia. |
| Lumbar ESPB | Active comparator | Procedure: Lumbar Erector Spinae Plane Block (L-ESPB)Participants will receive a lumbar Erector Spinae Plane Block (L-ESPB) performed under ultrasound guidance at the L4 transverse process level. A total of 20 mL of 0.2% ropivacaine will be injected deep to the erector spinae muscle and superficial to the transverse process. No sacral ESPB will be added. All participants will receive standardized spinal anesthesia and multimodal postoperative analgesia. |
Who may qualify
- Ages
- 65 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (5 listed)
- Adults aged 65 years or older scheduled to undergo elective hip arthroplasty under spinal anesthesia.
- Ability to provide written informed consent.
- Ability to understand and reliably use numerical pain assessment tools (NRS 0-10).
- ASA physical status II-III.
- Expected postoperative hospitalization of at least 48 hours to ensure complete data collection.
Key exclusion criteria (12 listed)
- Inability to provide informed consent due to cognitive impairment, language barrier, or severe hearing/speech limitations.
- Coagulopathy or therapeutic anticoagulation not meeting safety criteria for regional anesthesia.
- Local infection at the planned block site.
- Allergy, hypersensitivity, or contraindication to ropivacaine, local anesthetics, or study medications.
- Pre-existing lower-limb neurological deficits (motor or sensory) affecting outcome assessments.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pericapsular Nerve Group (PENG) BlockThe Pericapsular Nerve Group (PENG) block will be performed under ultrasound guidance using a curvilinear or linear transducer. A 22-gauge echogenic needle will be advanced in-plane toward the fascial plane between the iliopsoas tendon and the pelvic brim at the level of the anterior inferior iliac spine. A total of 20 mL of 0.2% ropivacaine will be injected incrementally with repeated aspiration to avoid intravascular injection. No additional peripheral nerve blocks will be performed. All patients will receive standardized spinal anesthesia and multimodal postoperative analgesia. | Procedure or surgery | PENG block |
| Suprainguinal Fascia Iliaca Compartment Block (S-FICB)The suprainguinal fascia iliaca compartment block will be performed under ultrasound guidance using a high-frequency linear probe placed in the sagittal oblique plane above the inguinal ligament. After identifying the fascia iliaca above the iliacus muscle, a 22-gauge echogenic needle will be advanced in-plane into the suprainguinal fascia iliaca space. A total of 30 mL of 0.2% ropivacaine will be injected to achieve cranial spread toward the femoral nerve, lateral femoral cutaneous nerve, and obturator nerve. All patients will receive standardized spinal anesthesia and multimodal postoperative analgesia. | Procedure or surgery | Suprainguinal FICB |
| Lumbar Erector Spinae Plane Block (L-ESPB)The lumbar erector spinae plane block will be performed under ultrasound guidance at the L4 transverse process level. A curvilinear or linear ultrasound probe will be used to identify the erector spinae muscle and underlying transverse process. A 22-gauge echogenic needle will be inserted in-plane and advanced to the fascial plane deep to the erector spinae muscle and superficial to the transverse process. A total of 20 mL of 0.2% ropivacaine will be injected incrementally. No sacral ESPB will be added. All patients will receive standardized spinal anesthesia and multimodal postoperative analgesia. | Procedure or surgery | Lumbar ESPB |
Primary outcome
Total Opioid Consumption in the First 48 Hours After Surgery
Time frame: 0-48 hours postoperatively
Total cumulative opioid consumption recorded in the first 48 postoperative hours, converted to morphine milligram equivalents (MME). Includes all opioid medications administered as part of postoperative analgesia, both scheduled and rescue doses. Data will be extracted from electronic medication records and converted using standard MME conversion factors.
19 secondary outcomes
Time to First Rescue Opioid Administration
Time frame: 0-48 hours postoperatively
Numerical Rating Scale (NRS) Pain Scores at Rest
Time frame: 4 hours postoperatively
Numerical Rating Scale (NRS) Pain Scores at Rest
Time frame: 8 hours postoperatively
Numerical Rating Scale (NRS) Pain Scores at Rest
Time frame: 12 hours postoperatively
Numerical Rating Scale (NRS) Pain Scores at Rest
Time frame: 24 hours postoperatively
Numerical Rating Scale (NRS) Pain Scores at Rest
Time frame: 48 hours postoperatively
Numerical Rating Scale (NRS) Pain Scores During Movement
Time frame: 4 hours postoperatively
Numerical Rating Scale (NRS) Pain Scores During Movement
Time frame: 8 hours postoperatively
Numerical Rating Scale (NRS) Pain Scores During Movement
Time frame: 12 hours postoperatively
Numerical Rating Scale (NRS) Pain Scores During Movement
Time frame: 24 hours postoperatively
Numerical Rating Scale (NRS) Pain Scores During Movement
Time frame: 48 hours postoperatively
Quadriceps Muscle Strength
Time frame: 4 hours postoperatively
Quadriceps Muscle Strength
Time frame: 8 hours postoperatively
Quadriceps Muscle Strength
Time frame: 12 hours postoperatively
Quadriceps Muscle Strength
Time frame: 24 hours postoperatively
Quadriceps Muscle Strength
Time frame: 48 hours postoperatively
Incidence of Postoperative Nausea and Vomiting (PONV)
Time frame: 0-24 hours postoperatively
Time to First Mobilization
Time frame: 0-48 hours postoperatively
Adverse Events Related to Regional Anesthesia
Time frame: Up to 48 hours postoperatively
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Mar 2026.
- Individual participant dataSharing planned: Yes. De-identified individual participant data (IPD) underlying the primary and secondary outcome analyses will be made available to other researchers upon reasonable request. Shared data will include demographic variables, intraoperative information, block-related details, pain scores, opioid consumption, motor assessments, and adverse events. No direct identifiers or protected health information will be included.
Related trials for Hip Osteoarthritis
Not yet recruiting
Effects of Low-Load Blood Flow Restriction Resistance Training With and Without Hip Abductor Strengthening in Patients With Knee Osteoarthritis.(BFR)
Knee Osteoarthritis
Recruiting
FRONT Block for Quality of Recovery After Total Hip Arthroplasty
Osteoarthritis of the Hip, Postoperative Pain
RecruitingObservational study
Post-Market Clinical Follow-up of Intra-Articular Hyaluronic Acid in Hip Osteoarthritis
Hip OA
Not yet recruitingObservational study
Clinical Validation of SMARTDIAGO for Remote Functional Assessment of Musculoskeletal Conditions
Knee Osteoarthristis, Hip Osteoarthritis
RecruitingObservational study
Z1 Hip System: Post-Market Clinical Follow Up Study
Hip Osteoarthritis, Acute Traumatic Fracture of the Femoral Head or Neck
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Malgorzata Reysner, MD PhD study chair
Poznań University of Medicla Sciences
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Pericapsular Nerve Group (PENG) Block, Suprainguinal Fascia Iliaca Compartment Block (S-FICB) and Lumbar Erector Spinae Plane Block (L-ESPB) in people with Hip Osteoarthritis, run by Poznan University of Medical Sciences at 1 site in Poland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Poland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Malgorzata Reysner, MD PhD (+48 61 873 83 03, mreysner@ump.edu.pl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Total Opioid Consumption in the First 48 Hours After Surgery (time frame: 0-48 hours postoperatively). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Mar 2026.